Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun 20;1(1):7.
doi: 10.1186/2191-219X-1-7.

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma

Franz Buchegger  1 , Oliver W Press
Affiliations

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma

Franz Buchegger et al. EJNMMI Res. .

Abstract

Several reports have documented similar efficacies and tolerable toxicities of radioimmunotherapy (RIT) consolidation and rituximab maintenance after initial R-chemotherapy of follicular lymphoma. The relative merits of these two interventions are currently under discussion. We now raise the question whether both RIT consolidation and rituximab maintenance should be used together aiming to augment the results achievable with R-chemotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Illidge TM. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? J Clin Oncol. 2010;28:2944–2946. doi: 10.1200/JCO.2009.26.8748. - DOI - PubMed
    1. Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Bischof Delaloye AB, Press OW, Ketterer N. Six of 12 relapsed refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med. 2011;52:896–900. doi: 10.2967/jnumed.111.087460. - DOI - PubMed
    1. Kaminski MS, Zelenetz AD, Press OW, Saleh MN, Leonard JP, Fehrenbacher L, Lister TA, Horner TJ, Williams VC, Lin TS, Vleisides C, Knox SJ, Wahl RL, Vose MJ. Tositumomab and I 131 Tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low grade and transformed B-cell lymphomas. Blood. 2010;116:Abstract 3960.
    1. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143–4149. doi: 10.1200/JCO.2006.05.8198. - DOI - PubMed
    1. Martin P, Coleman M, Furman RR, Vallabhajosula S, Kim DS, Edelstein A, Morrison J, Elstrom R, Ruan J, Goldsmith SJ, Leonard JP. Fludarabine plus I-131 tositumomab as initial treatment for follicular lymphoma: half of patients in remission at over 10 years median followup. Blood. 2010;116:Abstract 1785.

LinkOut - more resources